Display Settings:

Format

Send to:

Choose Destination
    Science. 2006 May 26;312(5777):1175-8.

    Targeting tyrosine kinases in cancer: the second wave.

    Source

    Oncology Program, Vall d'Hebron University Hospital and Vall d'Hebron Research Institute, Universidad Autónoma de Barcelona, Barcelona 08035, Spain. jbaselga@vhebron.net

    Abstract

    One of the most exciting developments in cancer research in recent years has been the clinical validation of molecularly targeted drugs that inhibit the action of pathogenic tyrosine kinases. Treatment of appropriately selected patients with these drugs can alter the natural history of their disease and improve survival. The clinical validation of these "first-generation" tyrosine kinase inhibitors has been the prelude to a second wave of advances in molecular targeting that is expected to further change the way we classify and treat cancer. Efforts are now being directed at identifying the tumor subtypes and patients who will benefit the most from these drugs. In addition, new compounds that circumvent acquired resistance to the first-generation tyrosine kinase inhibitors are being tested in patients with refractory disease. Agents directed against new molecular targets are also being explored.

    PMID:
    16728632
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Click here to read

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk